326 related articles for article (PubMed ID: 31894464)
1. O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease.
Park J; Lai MKP; Arumugam TV; Jo DG
Neuromolecular Med; 2020 Jun; 22(2):171-193. PubMed ID: 31894464
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond.
Yuzwa SA; Vocadlo DJ
Chem Soc Rev; 2014 Oct; 43(19):6839-58. PubMed ID: 24759912
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
Gong CX; Liu F; Iqbal K
Alzheimers Dement; 2016 Oct; 12(10):1078-1089. PubMed ID: 27126545
[TBL] [Abstract][Full Text] [Related]
5. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.
Liu F; Shi J; Tanimukai H; Gu J; Gu J; Grundke-Iqbal I; Iqbal K; Gong CX
Brain; 2009 Jul; 132(Pt 7):1820-32. PubMed ID: 19451179
[TBL] [Abstract][Full Text] [Related]
6. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation of amyloid-β precursor protein at threonine 576 residue regulates trafficking and processing.
Chun YS; Kwon OH; Chung S
Biochem Biophys Res Commun; 2017 Aug; 490(2):486-491. PubMed ID: 28624365
[TBL] [Abstract][Full Text] [Related]
8. The hexosamine signaling pathway: deciphering the "O-GlcNAc code".
Love DC; Hanover JA
Sci STKE; 2005 Nov; 2005(312):re13. PubMed ID: 16317114
[TBL] [Abstract][Full Text] [Related]
9. The emerging link between O-GlcNAc and Alzheimer disease.
Zhu Y; Shan X; Yuzwa SA; Vocadlo DJ
J Biol Chem; 2014 Dec; 289(50):34472-81. PubMed ID: 25336656
[TBL] [Abstract][Full Text] [Related]
10. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies.
Pinho TS; Correia SC; Perry G; Ambrósio AF; Moreira PI
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2048-2059. PubMed ID: 30412792
[TBL] [Abstract][Full Text] [Related]
11. Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets.
Bolanle IO; Riches-Suman K; Williamson R; Palmer TM
Pharmacol Res; 2021 Mar; 165():105467. PubMed ID: 33515704
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAcylation of protein kinase A catalytic subunits enhances its activity: a mechanism linked to learning and memory deficits in Alzheimer's disease.
Xie S; Jin N; Gu J; Shi J; Sun J; Chu D; Zhang L; Dai CL; Gu JH; Gong CX; Iqbal K; Liu F
Aging Cell; 2016 Jun; 15(3):455-64. PubMed ID: 26840030
[TBL] [Abstract][Full Text] [Related]
13. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.
Tramutola A; Sharma N; Barone E; Lanzillotta C; Castellani A; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Gaetani S; Cassano T; Perluigi M; Di Domenico F
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3309-3321. PubMed ID: 30031227
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcylation and neurodegeneration.
Wani WY; Chatham JC; Darley-Usmar V; McMahon LL; Zhang J
Brain Res Bull; 2017 Jul; 133():80-87. PubMed ID: 27497832
[TBL] [Abstract][Full Text] [Related]
15. O-GlcNAcylation and neuronal energy status: Implications for Alzheimer's disease.
Pinho TS; Verde DM; Correia SC; Cardoso SM; Moreira PI
Ageing Res Rev; 2018 Sep; 46():32-41. PubMed ID: 29787816
[TBL] [Abstract][Full Text] [Related]
16. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.
Zuliani I; Lanzillotta C; Tramutola A; Francioso A; Pagnotta S; Barone E; Perluigi M; Di Domenico F
Neurotherapeutics; 2021 Jan; 18(1):340-363. PubMed ID: 33258073
[TBL] [Abstract][Full Text] [Related]
17. O-GlcNAcylation, a sweet link to the pathology of diseases.
Nie H; Yi W
J Zhejiang Univ Sci B; 2019 May; 20(5):437-448. PubMed ID: 31090269
[TBL] [Abstract][Full Text] [Related]
18. Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer's disease.
Zheng BW; Yang L; Dai XL; Jiang ZF; Huang HC
Neurol Res; 2016 Feb; 38(2):177-86. PubMed ID: 27078700
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAc modification in diabetes and Alzheimer's disease.
Dias WB; Hart GW
Mol Biosyst; 2007 Nov; 3(11):766-72. PubMed ID: 17940659
[TBL] [Abstract][Full Text] [Related]
20. O-GlcNAcylation promotes non-amyloidogenic processing of amyloid-β protein precursor via inhibition of endocytosis from the plasma membrane.
Chun YS; Park Y; Oh HG; Kim TW; Yang HO; Park MK; Chung S
J Alzheimers Dis; 2015; 44(1):261-75. PubMed ID: 25208619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
